Medifast Reports First Quarter 2026 Results Amid Strategic Shift Toward Metabolic Health
Medifast, a company focused on metabolic health and wellness through its science-backed, coach-guided lifestyle programs, announced its financial results for the first quarter ended March 31, 2026. The results reflect both ongoing operational challenges and early signs of progress as the company continues to reposition its business for long-term growth.
Performance Overview
For the first quarter of 2026, Medifast reported total revenue of $76.0 million, representing a significant decline of 34.3% compared to $115.7 million in the same period last year. The drop in revenue was largely attributed to a continued reduction in the number of active earning coaches, a key driver of the company’s direct-selling model.
The company recorded a net loss of $2.1 million, or $0.19 per diluted share, compared to a net loss of $0.8 million, or $0.07 per share, in the first quarter of 2025. Despite the widening loss, Medifast maintained a strong balance sheet, ending the quarter with $168.9 million in cash, cash equivalents, and investment securities, and no outstanding debt.
Coach Network Trends
A central factor impacting performance was the decline in the number of independent active earning coaches. During the quarter, the total number of active coaches fell to 14,000, a decrease of 44.9% from 25,400 in the prior year period. This reduction reflects ongoing challenges in customer acquisition and broader shifts in the weight-loss market.
One notable industry trend affecting Medifast’s business is the rapid adoption of GLP-1 medications for weight loss, which has altered consumer behavior and demand patterns. These pharmaceutical options have created additional competition for traditional lifestyle and nutrition-based programs.
Despite the decline in coach count, the company reported improved productivity among its remaining coaches. Revenue per active earning coach rose to $5,432, an increase of 19.2% from $4,556 in the prior year. This improvement suggests that Medifast is successfully prioritizing higher-performing coaches and optimizing the efficiency of its network.
Profitability and Expenses
Gross profit for the quarter totaled $51.8 million, down 38.6% from $84.2 million in the first quarter of 2025. The decline was primarily due to lower sales volumes. Gross margin also contracted, with gross profit representing 68.1% of revenue, compared to 72.8% in the prior year. The margin compression was largely driven by reduced leverage on fixed costs as revenue declined.
Selling, general, and administrative (SG&A) expenses decreased significantly to $55.1 million, a 35.6% reduction from $85.5 million in the same period last year. Several factors contributed to this decline:
- A $16.2 million reduction in coach compensation due to lower sales volume and fewer active coaches
- A $5.6 million decrease in company-led marketing expenses
- A one-time gain of $2.2 million from the sale of the company’s Maryland distribution center
- A $2.0 million reduction in employee compensation following workforce realignment
As a percentage of revenue, SG&A expenses improved slightly to 72.4%, down from 73.9% in the prior year. While cost-cutting measures helped offset some revenue pressure, the company still experienced a loss from operations of $3.3 million, compared to $1.3 million in the first quarter of 2025.
Other Income and Taxes
Other income for the quarter was $1.4 million, a decrease of 24.3% from $1.8 million in the prior year. This decline was primarily due to unrealized gains on an investment in LifeMD common stock recorded in the prior year period. Medifast exited this investment during the second quarter of 2025.
Income tax expense for the quarter was minimal at $0.2 million, reflecting an effective tax rate of negative 9.3%. This compares to a tax expense of $1.3 million and an unusually high effective rate of 246.8% in the prior year. The current period’s lower tax expense is largely due to the company’s valuation allowance on deferred tax assets and the impact of operating losses.
Strategic Direction and Leadership Commentary
CEO Dan Chard expressed cautious optimism about the company’s progress, emphasizing improvements in key operational metrics. According to Chard, Medifast has now achieved two consecutive quarters of year-over-year growth in coach productivity, along with stronger leadership development within its coach network.
He highlighted that these indicators have historically preceded broader business recovery and growth. The company is continuing to invest in its metabolic health strategy, which focuses on combining scientific research, personalized coaching, and disciplined cost management.
Chard noted that while external pressures persist, particularly from evolving market dynamics, the company believes it is building a foundation for improved performance in the second half of 2026 and beyond.
Balance Sheet Strength
One of Medifast’s key strengths remains its solid financial position. As of March 31, 2026, the company reported:
- $168.9 million in cash, cash equivalents, and investment securities
- Zero debt
- Working capital of $160.4 million, up slightly from $158.7 million at the end of 2025
This strong liquidity provides the company with flexibility to navigate current challenges and continue investing in its transformation strategy.
Outlook for 2026
Looking ahead, Medifast provided guidance for both the second quarter and full year 2026. For the second quarter, the company expects:
- Revenue between $60 million and $80 million
- Loss per share in the range of $0.50 to $1.00
For the full year 2026, Medifast forecasts:
- Revenue between $270 million and $300 million
- Loss per share ranging from $1.55 to $2.75
The outlook reflects continued headwinds, particularly related to declining coach numbers and shifting market conditions. However, the company remains focused on stabilizing its business and returning to sustainable growth over the long term.
Investor Communication
Medifast scheduled its first quarter earnings conference call for May 4, 2026, at 4:30 p.m. Eastern Time. The call was made available via webcast on the company’s investor relations website, with an archived replay accessible through August 4, 2026. A telephonic replay option was also provided for a limited time following the call.
Medifast’s first quarter 2026 results highlight a company in transition. While revenue and profitability remain under pressure due to structural changes in the weight-loss industry and a shrinking coach network, there are early signs of operational improvement. Increased productivity among coaches, disciplined cost management, and a strong balance sheet position the company to weather near-term challenges.
As Medifast continues to pivot toward a broader metabolic health strategy, its ability to adapt to evolving consumer preferences and competitive dynamics will be critical. The coming quarters will likely determine how effectively the company can translate its strategic initiatives into sustained financial recovery and long-term growth.
About Medifast®:
Medifast is the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system. Designed to help address the challenges of metabolic dysfunction, the company’s holistic approach integrates personalized plans, scientifically developed products and a framework for habit creation — all supported by a dedicated network of independent coaches.
Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization®, a breakthrough science that reverses metabolic dysfunction through a targeted reset. Research demonstrates the company’s comprehensive system activates strong and targeted fat burn to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass and protecting muscle integrity.
Backed by more than 40 years of clinical heritage, Medifast continues to advance its mission of Lifelong Transformation, Making Healthy Lifestyle Second Nature
